JPMorgan Chase & Co. increased its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 44.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 393,474 shares of the company's stock after acquiring an additional 121,219 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.80% of Prestige Consumer Healthcare worth $30,726,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also recently bought and sold shares of PBH. Raymond James Financial Inc. acquired a new stake in Prestige Consumer Healthcare in the 4th quarter worth about $42,593,000. Boston Trust Walden Corp raised its position in shares of Prestige Consumer Healthcare by 43.5% in the 4th quarter. Boston Trust Walden Corp now owns 831,627 shares of the company's stock worth $64,942,000 after buying an additional 252,089 shares during the period. Natixis Advisors LLC boosted its holdings in Prestige Consumer Healthcare by 1,335.1% in the fourth quarter. Natixis Advisors LLC now owns 209,246 shares of the company's stock valued at $16,340,000 after acquiring an additional 194,665 shares during the last quarter. Wellington Management Group LLP purchased a new stake in Prestige Consumer Healthcare during the third quarter valued at about $6,342,000. Finally, Great Lakes Advisors LLC increased its stake in Prestige Consumer Healthcare by 113.7% during the fourth quarter. Great Lakes Advisors LLC now owns 139,116 shares of the company's stock worth $10,864,000 after acquiring an additional 74,016 shares during the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the company. Royal Bank of Canada boosted their target price on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a "sector perform" rating in a report on Friday, March 21st. StockNews.com lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Tuesday. Canaccord Genuity Group raised their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Oppenheimer upped their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Finally, Raymond James raised Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $93.33.
Check Out Our Latest Report on Prestige Consumer Healthcare
Insider Buying and Selling
In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now directly owns 17,157 shares of the company's stock, valued at $1,544,130. This trade represents a 8.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.60% of the company's stock.
Prestige Consumer Healthcare Stock Up 1.8 %
NYSE:PBH traded up $1.46 on Friday, reaching $82.17. The stock had a trading volume of 357,520 shares, compared to its average volume of 283,589. The company has a 50-day moving average of $84.56 and a 200 day moving average of $79.83. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The stock has a market cap of $4.07 billion, a P/E ratio of 19.24, a price-to-earnings-growth ratio of 2.69 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $90.04.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.
Prestige Consumer Healthcare Profile
(
Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Further Reading
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
